In an attempt to bolster its neurology pipeline, Karuna Therapeutics has agreed to pay Goldfinch Bio US$15 M upfront and up to US$520 M in potential milestone payments for the latter’s investigational transient receptor potential canonical 4 and 5 (TRPC4/5) channel candidates. Karuna will obtain an exclusive global license to develop, manufacture, and commercialise these candidates, including lead clinical-stage drug GFB-887 for the treatment of mood and anxiety disorders. These assets complement Karuna’s existing pipelinewhich includes leading schizophrenia drug, KarXT.